AbbVie Still Has Room To Run (NYSE:ABBV)
· seekingalpha.com
AbbVie stock outlook: Skyrizi & Rinvoq fuel EPS growth as Humira declines. Forward P/E and PEG suggest undervaluation.
Back in May, I reiterated my buy rating on AbbVie Inc. ( ABBV ) for the third consecutive time as it was shown that their overall business was robust in Q1 desp...